Savant Capital’s Generate Biomedicines GENB Stock Holding History

Savant Capital’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.09M	Buy	+139,418	New	+$2.14M	0.01%	816

Other funds holding GENB

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return

Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return

Savant Capital's GENB Position: Q3 2026 in Review

Savant Capital opened a new position in Generate Biomedicines (GENB) in Q3 2026: 139,418 shares worth $2.09M. The stake represents 0.01% of the portfolio and ranks #816 among its holdings.

35 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

Savant Capital held 139,418 shares of Generate Biomedicines worth $2.09M as of Q3 2026.
Generate Biomedicines was a new Savant Capital position in Q3 2026.
Generate Biomedicines made up 0.01% of Savant Capital's portfolio in Q3 2026, its #816 holding.
35 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.